Articles

Outcomes Associated with Conventional Salvage Therapy in Patients with Refractory or Relapsed AML and IDH1/IDH2 Mutations

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Overall Survival Benefit in Relapsed and Refractory B-Cell ALL Patients Receiving Inotuzumab Ozogamicin

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Presidential Symposium: Friday, June 10

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem-Cell Transplantation for De Novo ALL in Adults

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Response-Adapted Sequential Azacitidine and Intensive Chemotherapy Is Effective in Patients Aged >60 Years with Newly Diagnosed AML

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Valuable New Prognostic Scoring System in Patients with CML Receiving Nilotinib as Initial Treatment

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Venetoclax Is Safe and Effective When Combined with Rituximab in Relapsed CLL

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Page 163 of 330